Our Journal Articles
Al, P., Hey, S., Weijer, C., Gillies, K., McCleary, N., Yee, M. L., Inglis, J., Presseau, J., & Brehaut, J. (2023). Changing patient preferences toward better trial recruitment: an ethical analysis. Trials, 24(1), 233. https://doi.org/10.1186/s13063-023-07258-4
Seung, S.J., Saherawala, H., Moldaver, D., Shokar, S., Ammendolea, C., Brezden-Masley, C. (2023). Survival, treatment patterns, and costs of HER2+ metastatic breast cancer patients in Ontario between 2005 to 2020. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-023-07185-7
Brehaut, J. C., Carroll, K., Gordon, J., Presseau, J., Richards, D. P., Fergusson, D. A., Graham, I. D., et al. (2021). Results from a theory-guided survey to support breast cancer trial participation: Barriers, enablers, and what to do about them. Current Oncology, 28(3), 2014–2028. http://dx.doi.org/10.3390/curroncol28030187
Cardoso, F., Wilking, N., Bernardini, R., Biganzoli, L., Espin, J., Miikkulainen, K., Schuurman, S., Spence, D., Spitz, S., Ujupan, S., Zernik, N., & Gordon, J. (2020). A multi-stakeholder approach in optimising patients’ needs in the benefit assessment process of new metastatic breast cancer treatments. The Breast, 52, 78-87. https://doi.org/10.1016/j.breast.2020.04.011
Dent, S., Ammendolea, C., Christofides, A., Edwards, S., Incekol, D., Pourmirza, B., Kfoury, S., et al. (2019). A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer. Current Oncology, 26(1), 70–80. http://dx.doi.org/10.3747/co.26.4220